Challenges And Strategies To Automate Potency Assays To Be Discussed By Catalent Expert At Upcoming CASSS Bioassays Symposium




SOMERSET, N.J. – May 3, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Christopher Hepler, Group Leader in Biologics Analytical Services at Catalent’s site in Research Triangle Park, North Carolina, will be presenting at the upcoming CASSS Bioassays Symposium, to be held at the DoubleTree by Hilton Hotel in Silver Spring, Maryland, on May 8 – 9, 2017.

Mr. Hepler’s presentation, on Monday, May 8 at 2:25 p.m., is entitled “Automation of Friendly Assay Design,” and will discuss the challenges of adapting potency assays to robotic systems. Attempts to integrate quantitative and potency assays using Hamilton® Robotics systems, including assays based on proteins, nucleic acids and cells will be presented and the results, both positive and unsuccessful, will be demonstrated. Additionally, Mr. Hepler will discuss strategies and lessons learned to optimize and validate successful automation.

Mr. Hepler is a 20-year veteran of the pharmaceutical and biopharmaceutical industry and has extensive validation and project management experience operating under Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). He has expertise in protein purification, biochemical assays and laboratory automation. He holds a bachelor’s degree in animal science and master’s degree in physiology, both from North Carolina State University.

Additionally, on Monday, May 8 at 1:30 p.m., Mike Merges, Director of Strategic Growth, Catalent Biologics Analytical Services, will be co-chairing a session on new bioassay approaches and technologies, where a series of presentations will highlight different approaches to accurately and robustly measure the potency of emerging therapeutics.

For more information on the CASSS Bioassays Symposium, visit Catalent/CASSS and to arrange a meeting with Mr. Hepler or Mr. Merges at the event, contact Richard Kerns at NEPR - richard@nepr.eu.

For more information on Catalent Biologics visit www.CatalentBiologics.com

Media Contacts:

Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0)161 728 5880
richard@nepr.eu

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

More products. Better treatments. Reliably supplied.™

Hamilton is a registered trademark of the Hamilton Company